Postmarketing surveillance for Manusept viruzid (1 minute application time) revealed that, since its introduction to the market in 2007, a total of 94 suspected cases of adverse effects have been reported with sometimes severe skin irritation and obvious damage to the skin barrier. The calculated frequency of suspected adverse effects was 0.019 cases per litre. For Sterillium Virugard without phosphoric acid the number of cases of suspected adverse effects calculated for the last 8 years was 0.0000023 cases per litre. The faster virucidal activity of the currently available preparations is apparently achieved only at the price of poorer dermal tolerance. That is why the advantages of faster virucidal activity should be carefully balanced in clinical practice with its evident disadvantages
